Showing results (191-200 of 398) with videos related to
Sort By:
Pageof 40
FEBS Letters|February 3, 1992
Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin LL Goretzki, M Schmitt, K Mann, et al.The Journal of Biological Chemistry|March 15, 1991
Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA)H Kobayashi, M Schmitt, L Goretzki, et al.Plos One|November 13, 2012
Parental acceptance of HPV vaccine in Peru: a decision frameworkRosario M Bartolini, Jennifer L Winkler, Mary E Penny, et al.Thrombosis Research|December 15, 1988
The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patientsG Ostermann, A Lang, H Holtz, et al.Cancer Research|June 15, 1988
Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stromaO Wilhelm, R Hafter, E Coppenrath, et al.Histopathology|September 1, 1991
Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectumC F Sier, C Fellbaum, H W Verspaget, et al.Thrombosis and Haemostasis|July 1, 1997
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapyM Schmitt, N Harbeck, C Thomssen, et al.British Journal of Cancer|July 17, 1999
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-upN Harbeck, P Dettmar, C Thomssen, et al.Journal of Obstetrics and Gynaecology (Tokyo, Japan)|April 1, 1995
Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasisM Schmitt, O Wilhelm, F Jänicke, et al.Anticancer Research|August 15, 1998
Prognostic impact of tumor biological factors on survival in node-negative breast cancerN Harbeck, P Dettmar, C Thomssen, et al.Pageof 40